Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00701727 · ClinicalTrials.gov registry record · Phase 4
Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study
A Phase 4 study, sponsored by Radiant Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00701727 is a Phase 4 study that has completed, run by Radiant Research. The registered enrollment target is 31 participants.
The verdict
NCT00701727, a Phase 4 study, has completed, sponsored by Radiant Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a prospective, placebo-controlled, cross-over trial comparing the the effects of approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on several parameters of reverse cholesterol transport (RCT) in men and post-menopausal women diagnosed with hypercholesterolemia. The primary hypothesis is that the ezetimibe treatment will increase the excretion of endogenous (plasma-derived) cholesterol as fecal sterols, with secondary hypotheses that there will be a significant increase in de novo cholesterol synthesis, treatment will increase cholesterol efflux from tissues into the bloodstream, and increase global RCT.
Interventions
- DRUG Placebo
- DRUG ezetimibe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00701727
The ClinicalTrials.gov registry entry for NCT00701727 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiant Research, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00701727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00701727 about?
NCT00701727 is a clinical study titled "Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study". This is a prospective, placebo-controlled, cross-over trial comparing the the effects of approximately 7 weeks of placebo treatment to 7 weeks of ezetimibe (10mg/day) treatment on several parameters of reverse cholesterol transport (RCT) in men and post-menopausal women diagnosed with hypercholester...
What is the current status of trial NCT00701727?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2008-06. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00701727?
The interventions under investigation include: Placebo (DRUG), ezetimibe (DRUG).
Who is sponsoring clinical trial NCT00701727?
This trial is sponsored by Radiant Research, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.